PellePharm
PellePharm is a clinical-stage biopharmaceutical company developing patidegib, a topical hedgehog pathway inhibitor, to treat patients with Basal Cell Nevus Syndrome (Gorlin Syndrome), a rare genetic disorder causing basal cell carcinoma susceptibility.
- Company typePrivate
- Founded2012
- HeadquartersMenlo Park, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
PellePharm firmographics
Firmographics- Name
- PellePharm
- Website
- https://pellepharm.com
- Company type
- Private
- Founded year
- 2012
- Headcount range
- 11–50 employees
- Short description
- PellePharm is a clinical-stage biopharmaceutical company developing patidegib, a topical hedgehog pathway inhibitor, to treat patients with Basal Cell Nevus Syndrome (Gorlin Syndrome), a rare genetic disorder causing basal cell carcinoma susceptibility.
- Ownership category
- akta.pro rank
PellePharm industry classification
Industry- Product category
- Dermatology Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)
- akta.pro secondary industry
- Dermatology Specialty Pharmaceuticals (HLAIACAL)
Keywords
Where PellePharm is headquartered
LocationHeadquarters
- HQ city
- Menlo Park
- HQ country
- United States
- HQ region
- North America
Markets served
PellePharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
PellePharm product offering
Product offeringCore offering
PellePharm develops patidegib, a proprietary hedgehog pathway inhibitor intended to reduce the tumor burden of basal cell carcinomas in patients with Basal Cell Nevus Syndrome (BCNS/Gorlin Syndrome). The company's efforts center on advancing this investigational topical therapeutic through clinical development for a rare genetic dermatologic oncology indication with limited treatment options.
Differentiator
Problem solved
Functional benefit
Products and services
- Patidegib
Companies that use PellePharm
Customer profileSegments1 record
Ideal customer profiles1 record
PellePharm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
PellePharm competitors and assessment
Company assessmentOthers
- BridgeBio Pharma: Lead investor in PellePharm's 2017 Series B and a rare-disease-focused biotech platform with overlapping expertise in genetic and oncologic conditions, potentially serving as a parent/strategic acquirer.
- Aisling Capital: Late-stage healthcare-focused investor that participated in PellePharm's 2018 financing — relevant as a comparable biotech investor with portfolio company overlap.
Broad incumbents
- Novartis: Markets Erivedge (vismodegib), an FDA-approved hedgehog pathway inhibitor for advanced basal cell carcinoma — the most direct systemic competitor to PellePharm's patidegib in BCC/BCNS.
- Sun Pharma: Markets Odomzo (sonidegib), another FDA-approved hedgehog pathway inhibitor for locally advanced BCC — a direct mechanistic competitor to patidegib.
- Regeneron: Markets Libtayo (cemiplimab), a PD-1 inhibitor approved for advanced BCC — a competing modality for the same patient population PellePharm targets.
Emerging players
- Palobiofarma: Emerging biotech developing hedgehog pathway inhibitors (e.g., taladegib) for oncology indications, representing a peer-stage competitor in the same mechanistic class as PellePharm.
Market position
Customer concentration
PellePharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
PellePharm leadership team
Management profileNumber of profiles
Profiles6 records
PellePharm funding detail
Funding detailFunding overview
Funding rounds8 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PellePharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PellePharm
What does PellePharm do?
PellePharm develops patidegib, a proprietary hedgehog pathway inhibitor intended to reduce the tumor burden of basal cell carcinomas in patients with Basal Cell Nevus Syndrome (BCNS/Gorlin Syndrome). The company's efforts center on advancing this investigational topical therapeutic through clinical development for a rare genetic dermatologic oncology indication with limited treatment options.
When was PellePharm founded?
PellePharm was founded in 2012. It employs 11 to 50 people.
Where is PellePharm based?
PellePharm is headquartered in Menlo Park, United States, in the North America region.
Who are PellePharm's main competitors?
Others on record are BridgeBio Pharma and Aisling Capital. Broad incumbents are Novartis, Sun Pharma and Regeneron. Palobiofarma is listed as an emerging player.
Does PellePharm have an API?
No public API is recorded for PellePharm.
What industry is PellePharm in?
PellePharm's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.